Biopharma companies develop medicines, vaccines and advanced therapies to prevent, treat and manage disease. The sector spans drug discovery, clinical development, manufacturing and commercialisation across a wide range of therapeutic areas.
This category includes companies working on:
Browse 304 UK biopharma companies below.
IgE and IgA antibody therapeutics for cancer treatment
Epsilogen is a clinical-stage biotech pioneering the development of non-IgG immunoglobulin antibody therapeutics for cancer. The company's platform spans IgE, IgA, and IgG isotypes, enabling selection of the most appropriate antibody format for a given tumour type. Its lead candidate MOv18 IgE, the first IgE antibody…
Steroid-free dermatology formulations and investigational GL-1 platform
Gran Lab is a Queen's University Belfast spin-out developing biochemical formulations for inflammatory and reactive skin conditions. Its investigational GL-1 topical platform is being developed as a non-steroidal approach to psoriasis and related dermatoses, with laboratory studies ongoing and clinical trials in…
AI drug discovery platform targeting neurological diseases
CoSyne Therapeutics is a drug discovery company applying AI and computational methods to identify and develop therapeutics for neurological diseases. The company describes its approach as polymathic AI, integrating models across biology, chemistry, and genomics to generate and prioritise drug targets. CoSyne operates…
Ex vivo haematopoietic stem cell gene therapies for rare genetic diseases
Orchard Therapeutics is a gene therapy company developing ex vivo haematopoietic stem cell therapies for rare genetic diseases, primarily severe neurometabolic and immunological disorders in children. Its platform modifies a patient's own stem cells with a functional copy of the defective gene before reinfusion. Lead…
Human ovarian cell models and multi-omics drug discovery
OvartiX is a Cambridge biotechnology company developing drug-discovery tools and therapeutic programmes for ovarian and reproductive health. Its platform combines human multi-omics datasets, machine learning and engineered two- and three-dimensional ovarian cell models to identify and validate disease targets. Founded…
AAV gene therapies for neurodegenerative diseases including FTD and ALS
AviadoBio is a clinical-stage gene therapy company developing AAV-based treatments for neurodegenerative diseases. Its lead programme, AVB-101, is in a Phase 1/2 trial for frontotemporal dementia caused by GRN gene mutations, delivering a functional copy of the GRN gene via intrathalamic infusion to restore…
Animal health medicines and APIs manufactured for global markets
Elanco UK is the principal UK subsidiary of Elanco Animal Health Incorporated, a global animal health company developing and manufacturing products for farm animals and pets. Its primary UK manufacturing site in Speke, Liverpool produces fermentation-derived active pharmaceutical ingredients and finished veterinary…
ACE inhibitors for safer cardiovascular and fibrosis treatment
Angiodesign is a seed-stage drug discovery company developing next-generation domain-selective inhibitors of angiotensin-converting enzyme (ACE). Unlike current-generation ACE inhibitors, which cause bradykinin accumulation and limiting side effects, Angiodesign's C-domain selective inhibitors aim to reduce blood…
CBD-based licensed medicines for chronic inflammatory pain
Ananda Pharma is an AQSE-listed UK biotechnology company developing pharmaceutical-grade cannabidiol formulations as licensed medicines for chronic inflammatory pain conditions. The company focuses on essentially THC-free CBD products manufactured to UK pharmaceutical standards, targeting conditions including…
Therapeutic cancer vaccines based on recombinant overlapping peptide technology
Oxford Vacmedix is a clinical-stage biopharma company developing therapeutic cancer vaccines using its proprietary Recombinant Overlapping Peptide (ROP) platform. ROPs stimulate broad T cell and antibody immunity without HLA restriction, enabling a universal immunotherapy approach. The lead programme, OVM-200, targets…
Metal-based antimicrobial drugs and antibiofilm coating compounds
MetalloBio is a University of Sheffield spin-out developing metal-based antimicrobial compounds against drug-resistant bacterial infections. Its KLS-1 series includes investigational antibacterial candidate KLS-116, designed to act against multidrug-resistant pathogens and biofilms. The KLS-2 series is being developed…
Precision calcium channel medicines for epilepsy and Parkinson's disease
Lario Therapeutics is developing first-in-class precision medicines as disease-modifying treatments for severe neurological disorders, including genetically defined epileptic encephalopathies and Parkinson's disease. The company's pipeline centres on neuronal calcium channel inhibitors, beginning with genetically…
Inhaled antifungal therapies for serious respiratory fungal infections
Pulmocide is a late-stage biopharmaceutical company developing inhaled medicines for life-threatening respiratory fungal infections. Its lead compound opelconazole is a triazole antifungal designed for inhaled delivery to maximise pulmonary drug concentration while minimising systemic exposure and drug interactions.…
CAR T cell therapies for blood cancer and autoimmune disease
Autolus Therapeutics is a London-based commercial-stage biopharma developing next-generation programmed T cell therapies. Its lead product AUCATZYL (obecabtagene autoleucel) received FDA approval in November 2024 and MHRA conditional marketing authorisation in 2025 for relapsed or refractory B-cell acute lymphoblastic…
Global diabetes and cardiometabolic medicines leader
Novo Nordisk Limited is the UK commercial and medical affiliate of Novo Nordisk A/S, the Danish pharmaceutical company focused on diabetes, obesity, and cardiometabolic disease. The UK operation covers commercialisation, medical affairs, and clinical trial activities. Separately, Novo Nordisk Research Centre Oxford…
Platform for controlled, repeatable cellular rejuvenation therapeutics
BioRes is a preclinical biotechnology company developing a platform for controlled, repeatable cellular rejuvenation. The company's approach aims to restore cellular function as a way of addressing the underlying biological causes of age-related decline and disease, rather than treating individual conditions in…
Global biopharma focused on neurology and rare disease therapeutics
Biogen is a global biopharma company and one of the world's first biotechnology firms. The UK and Ireland headquarters in Maidenhead employs approximately 250 people across clinical operations, regulatory affairs, drug safety, and medical affairs. The company develops and commercialises therapies for neurological,…
GPCR-targeted small molecule drugs for rare and inflammatory disease
Trio Medicines is a small pharmaceutical company developing small molecule therapeutics targeting G-protein coupled receptors for diseases with unmet clinical need. Its pipeline includes gastrin/CCK2 receptor antagonists for gastric neuroendocrine tumours, a selective β2-adrenoceptor antagonist, and a formyl peptide…
Antibody therapeutics targeting glycosphingolipid inflammation
Protalea Bio is a biotech company developing first-in-class therapeutic antibodies to prevent progression from precancerous states to active blood cancers including multiple myeloma and B-cell lymphoma. The company's approach targets glycosphingolipid-related inflammation before disease onset, building on over fifteen…
Clinical-stage company developing radioligand cancer therapies
Blue Earth Therapeutics is a clinical-stage biotechnology company developing targeted radiopharmaceutical therapies for cancer. Its pipeline centres on prostate-specific membrane antigen-targeted radioligand therapies using both beta- and alpha-emitting radionuclides, designed to deliver high radiation doses to tumour…